Healthcare Industry News: HSMN NewsFeed
News Release - June 29, 2020
SFA Therapeutics Announces FDA Approval To Begin IND TrialClinical Trial Examines Human Micro-biome-based Drug SFA002 In Mild to Moderate Plaque Psoriasis
PHILADELPHIA, June 29, 2020 -- (Healthcare Sales & Marketing Network) -- SFA Therapeutics, Inc. is pleased to announce that the US FDA has provided approval to conduct a clinical trial (officially referred to as an IND) for the treatment of "the appearance of the structure of skin with plaques due to psoriasis." SFA plans to expand the evaluation of one of its five microbiome-derived drugs, SFA002, in this new trial.
This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 15 patients into treatment with an initial formulation of SFA002 and an additional 15 subjects into treatment with a second formulation. Treatment duration will be three months, after which patients will be observed for an additional three months.
The Need for an Oral Treatment of Mild to Moderate Psoriasis Remains Acute
"Significant clearing of psoriatic plaques has already been demonstrated with SFA002 in a small study," commented SFA CEO Dr. Ira Spector, "and, because we know that this patient group has lacked an effective and safe oral treatment option, we are going into this larger IND trial with considerable optimism."
Study recruitment is planned to begin in the Fall of 2020. Following the trial's completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial.
Please contact SFA Therapeutics COO, James Kirwin, at firstname.lastname@example.org for additional information.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting Psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit sfatherapeutics.com to learn more.
Source: SFA Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.